CU
Anavex Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANAVEX®2-73 (blarcamesine) | Alzheimer's Disease Dementia | Phase 2/3 |
| ANAVEX®1-41 | Neurodegenerative Diseases | Preclinical |
Leadership Team at Anavex Life Sciences
SB
Sandra Boenisch
Senior Vice President, Chief Financial Officer
WE
Walter E. Kaufmann, MD
Chief Medical Officer
SN
Stephan N. Schaefer, MD
Executive Vice President, Global Clinical Development
AS
Athanasios Skarpelos
Director
EA
Ellsworth Alvord, Jr.
Director